{
  "settings": {
    "eval_files_dir": "/teamspace/studios/this_studio/llm_evaluation/example_longhealth/outputs/logprob_evaluation",
    "num_verifiers": 5,
    "verifiers": [
      "Qwen/Qwen1.5-1.8B-Chat_NQ",
      "mistralai/Mistral-7B-Instruct-v0.3_NQ",
      "mistralai/Mistral-7B-Instruct-v0.3_Q",
      "tiiuae/falcon-7b-instruct_NQ",
      "tiiuae/falcon-7b-instruct_Q"
    ],
    "total_queries": 10
  },
  "summary_metrics": {
    "individual_accuracies_top1": {
      "Qwen/Qwen1.5-1.8B-Chat_NQ": 90.0,
      "mistralai/Mistral-7B-Instruct-v0.3_NQ": 90.0,
      "mistralai/Mistral-7B-Instruct-v0.3_Q": 90.0,
      "tiiuae/falcon-7b-instruct_NQ": 90.0,
      "tiiuae/falcon-7b-instruct_Q": 90.0
    },
    "full_agreement_count": 0,
    "full_agreement_rate": 0.0,
    "majority_agreement_count": 7,
    "majority_agreement_rate": 0.7
  },
  "agreement_details_by_query": {
    "patient_01_q0": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "D: Vincristine\n\nThe context provided does not mention Vincristine as part of the current treatment regimen for Mrs. Sample's DLBCL. The current treatment regimen includes Polatuzumab vedotin, Rituxim",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "D: Vincristine\n\nThe document mentions the following drugs in the current treatment regimen for Mrs. Sample's DLBCL: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubic",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "D: Vincristine\n\nThe document mentions the following drugs in the current treatment regimen for Mrs. Sample's DLBCL: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubic",
        "tiiuae/falcon-7b-instruct_NQ": "D: Vincristine\n\nExplanation: Vincristine is not listed in the current treatment regimen for Mrs. Sample's DLBCL. The regimen includes Polatuzumab vedotin, Rituximab, Cycloph",
        "tiiuae/falcon-7b-instruct_Q": "D: Vincristine is not part of the current treatment regimen for Mrs. Sample's DLBCL. The text mentions that the current treatment regimen includes Polatuzumab vedotin, Rituximab, Cyclophosph"
      },
      "choice_counts": {
        "D: Vincristine\n\nThe context provided does not mention Vincristine as part of the current treatment regimen for Mrs. Sample's DLBCL. The current treatment regimen includes Polatuzumab vedotin, Rituxim": 1,
        "D: Vincristine\n\nThe document mentions the following drugs in the current treatment regimen for Mrs. Sample's DLBCL: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubic": 2,
        "D: Vincristine\n\nExplanation: Vincristine is not listed in the current treatment regimen for Mrs. Sample's DLBCL. The regimen includes Polatuzumab vedotin, Rituximab, Cycloph": 1,
        "D: Vincristine is not part of the current treatment regimen for Mrs. Sample's DLBCL. The text mentions that the current treatment regimen includes Polatuzumab vedotin, Rituximab, Cyclophosph": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Plurality/Disagreement",
      "agreed_upon_choice": "D: Vincristine\n\nThe document mentions the following drugs in the current treatment regimen for Mrs. Sample's DLBCL: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubic"
    },
    "patient_01_q1": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "D: She has 3-vessel CHD.\nThe provided context states that Mrs. Sample has \"2-vessel CHD\" (coronary artery disease), not 3-vessel CHD. Therefore, the statement \"She has",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "D: She has 3-vessel CHD.\n\n---\n\nExplanation: The medical history section mentions \"2-vessel CHD\" but does not mention \"3-vessel CHD.\" Therefore, option D is the statement that is not accurate based on",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "D: She has 3-vessel CHD.\n\n---\n\nExplanation: The medical history section mentions \"2-vessel CHD\" but does not mention \"3-vessel CHD.\" Therefore, option D is the statement that is not accurate based on",
        "tiiuae/falcon-7b-instruct_NQ": "D: She has 3-vessel CHD.\nThe provided context mentions \"2-vessel CHD\" and does not mention 3-vessel CHD. Therefore, the correct answer is D.\nA: She has 2-vessel disease",
        "tiiuae/falcon-7b-instruct_Q": "D: She has 3-vessel CHD.\n\n---\n\nExplanation: The medical history section mentions \"2-vessel CHD\" but does not mention \"3-vessel CHD.\" Therefore, option D is the statement that is not accurate based on"
      },
      "choice_counts": {
        "D: She has 3-vessel CHD.\nThe provided context states that Mrs. Sample has \"2-vessel CHD\" (coronary artery disease), not 3-vessel CHD. Therefore, the statement \"She has": 1,
        "D: She has 3-vessel CHD.\n\n---\n\nExplanation: The medical history section mentions \"2-vessel CHD\" but does not mention \"3-vessel CHD.\" Therefore, option D is the statement that is not accurate based on": 3,
        "D: She has 3-vessel CHD.\nThe provided context mentions \"2-vessel CHD\" and does not mention 3-vessel CHD. Therefore, the correct answer is D.\nA: She has 2-vessel disease": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "D: She has 3-vessel CHD.\n\n---\n\nExplanation: The medical history section mentions \"2-vessel CHD\" but does not mention \"3-vessel CHD.\" Therefore, option D is the statement that is not accurate based on"
    },
    "patient_01_q2": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe context provided mentions \"Primary progressive type of multiple sclerosis (ID 03/02)\" as one of Mrs. Sample's other diagnoses, indicating that",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe context provided mentions \"Primary progressive type of multiple sclerosis (ID 03/02)\" as one of Mrs. Sample's other diagnoses, indicating that",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe context provided mentions \"Primary progressive type of multiple sclerosis (ID 03/02)\" as one of Mrs. Sample's other diagnoses, indicating that",
        "tiiuae/falcon-7b-instruct_NQ": "A: Primary progressive type of multiple sclerosis (ID 03/02)\nThe correct answer is A: Primary progressive type of multiple sclerosis (ID 03/02). This is mentioned in the \"Other diagnoses\" section of the",
        "tiiuae/falcon-7b-instruct_Q": "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe provided context clearly mentions that Mrs. Sample suffers from \"Primary progressive type of multiple sclerosis (ID 03/02)\", which is a chronic,"
      },
      "choice_counts": {
        "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe context provided mentions \"Primary progressive type of multiple sclerosis (ID 03/02)\" as one of Mrs. Sample's other diagnoses, indicating that": 3,
        "A: Primary progressive type of multiple sclerosis (ID 03/02)\nThe correct answer is A: Primary progressive type of multiple sclerosis (ID 03/02). This is mentioned in the \"Other diagnoses\" section of the": 1,
        "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe provided context clearly mentions that Mrs. Sample suffers from \"Primary progressive type of multiple sclerosis (ID 03/02)\", which is a chronic,": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "A: Primary progressive type of multiple sclerosis (ID 03/02) \n\nThe context provided mentions \"Primary progressive type of multiple sclerosis (ID 03/02)\" as one of Mrs. Sample's other diagnoses, indicating that"
    },
    "patient_01_q3": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "B: 0.5 mg, 1 capsule at bedtime\nAnswer:  B: 0.5 mg, 1 capsule at bedtime\n\nThe context provided states: \"Fingolimod - 0.5mg,",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "B: 0.5 mg, 1 capsule at bedtime\nAnswer: B: 0.5 mg, 1 capsule at bedtime\n\n---\n\nQuery: What is the most recent date of a therapy session for Mrs. Sample?\n\nOptions:",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "B: 0.5 mg, 1 capsule at bedtime\nAnswer: B: 0.5 mg, 1 capsule at bedtime\n\n---\n\nQuery: What is the most recent date of a therapy session for Mrs. Sample?\n\nOptions:",
        "tiiuae/falcon-7b-instruct_NQ": "B: Fingolimod 0.5mg, 1 capsule at bedtime, Note: Take a break as directed\nAnswer: B: Fingolimod 0.5mg, 1 capsule at bedtime, Note:",
        "tiiuae/falcon-7b-instruct_Q": "B: 0.5 mg, 1 capsule at bedtime\nAnswer:  B: 0.5 mg, 1 capsule at bedtime\n\nThe context provided states: \"Fingolimod - 0.5mg,"
      },
      "choice_counts": {
        "B: 0.5 mg, 1 capsule at bedtime\nAnswer:  B: 0.5 mg, 1 capsule at bedtime\n\nThe context provided states: \"Fingolimod - 0.5mg,": 2,
        "B: 0.5 mg, 1 capsule at bedtime\nAnswer: B: 0.5 mg, 1 capsule at bedtime\n\n---\n\nQuery: What is the most recent date of a therapy session for Mrs. Sample?\n\nOptions:": 2,
        "B: Fingolimod 0.5mg, 1 capsule at bedtime, Note: Take a break as directed\nAnswer: B: Fingolimod 0.5mg, 1 capsule at bedtime, Note:": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Plurality/Disagreement",
      "agreed_upon_choice": "B: 0.5 mg, 1 capsule at bedtime\nAnswer:  B: 0.5 mg, 1 capsule at bedtime\n\nThe context provided states: \"Fingolimod - 0.5mg,"
    },
    "patient_01_q4": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nBased on the oncology board decision mentioned in the discharge summary, the therapy regime recommended for Mrs. Sample is",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nBased on the oncology board decision mentioned in the discharge summary, the therapy regime recommended for Mrs. Sample is",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nThe oncology board decision is clearly stated in the document: \"Oncology board decision: 6 cycles",
        "tiiuae/falcon-7b-instruct_NQ": "D: 6 cycles of R-Pola-CHP\nThe oncology board decision: 6 cycles of R-Pola-CHP. **D:** 6 cycles of R-Pola-CHP. Based on the provided context,",
        "tiiuae/falcon-7b-instruct_Q": "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nBased on the oncology board decision mentioned in the discharge summary, the therapy regime recommended for Mrs. Sample is"
      },
      "choice_counts": {
        "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nBased on the oncology board decision mentioned in the discharge summary, the therapy regime recommended for Mrs. Sample is": 3,
        "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nThe oncology board decision is clearly stated in the document: \"Oncology board decision: 6 cycles": 1,
        "D: 6 cycles of R-Pola-CHP\nThe oncology board decision: 6 cycles of R-Pola-CHP. **D:** 6 cycles of R-Pola-CHP. Based on the provided context,": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "D: 6 cycles of R-Pola-CHP\nAnswer: D: 6 cycles of R-Pola-CHP\n\nBased on the oncology board decision mentioned in the discharge summary, the therapy regime recommended for Mrs. Sample is"
    },
    "patient_01_q5": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "C: Thoracic vertebra 10\nBased on the context provided, the metastasis that was surgically addressed was located at the level of T10. The relevant text from the initial report is:\n\n**Pathology**: Aggressive B",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "C: Thoracic vertebra 10\nThe metastasis that was surgically addressed was located at the thoracic vertebra 10 (T10). This information is derived from the initial admission and medical history provided, where it states",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "C: Thoracic vertebra 10\nThe metastasis that was surgically addressed was located at the thoracic vertebra 10 (T10). This information is derived from the initial admission and medical history provided, where it states",
        "tiiuae/falcon-7b-instruct_NQ": "C: Thoracic vertebra 10\n: There is a large intraspinal mass extending from T10-L1, causing an anterior spongy appearance of the spinal cord and resulting in complete spinal canal stenosis at this level",
        "tiiuae/falcon-7b-instruct_Q": "C: Thoracic vertebra 10\nBased on the context provided, the metastasis that was surgically addressed was located at the level of T10. The relevant text from the initial report is:\n\n**Pathology**: Aggressive B"
      },
      "choice_counts": {
        "C: Thoracic vertebra 10\nBased on the context provided, the metastasis that was surgically addressed was located at the level of T10. The relevant text from the initial report is:\n\n**Pathology**: Aggressive B": 2,
        "C: Thoracic vertebra 10\nThe metastasis that was surgically addressed was located at the thoracic vertebra 10 (T10). This information is derived from the initial admission and medical history provided, where it states": 2,
        "C: Thoracic vertebra 10\n: There is a large intraspinal mass extending from T10-L1, causing an anterior spongy appearance of the spinal cord and resulting in complete spinal canal stenosis at this level": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Plurality/Disagreement",
      "agreed_upon_choice": "C: Thoracic vertebra 10\nBased on the context provided, the metastasis that was surgically addressed was located at the level of T10. The relevant text from the initial report is:\n\n**Pathology**: Aggressive B"
    },
    "patient_01_q6": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nQuery: What is",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nQuery: What is",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nQuery: What is",
        "tiiuae/falcon-7b-instruct_NQ": "A: CT Chest/Abdomen/Pelvis + Contrast from 01/09/2017 Results: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT",
        "tiiuae/falcon-7b-instruct_Q": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nQuery: What is"
      },
      "choice_counts": {
        "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nQuery: What is": 4,
        "A: CT Chest/Abdomen/Pelvis + Contrast from 01/09/2017 Results: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nQuery: What is"
    },
    "patient_01_q7": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "B: MR Spine plain + post-contrast from 12/20/2016 10:00 AM, MR Head 3D unenhanced + contrast from 12/19/20",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "B: MR Spine plain + post-contrast from 12/20/2016 10:00 AM, MR Head 3D unenhanced + contrast from 12/19/20",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "B: MR Spine plain + post-contrast from 12/20/2016 10:00 AM, MR Head 3D unenhanced + contrast from 12/19/20",
        "tiiuae/falcon-7b-instruct_NQ": "B: MR Head 3D unenhanced + contrast from 12/19/2016 10:30 AM. MR Spine plain + post-contrast from 12/20/20",
        "tiiuae/falcon-7b-instruct_Q": "B: MR Spine plain + post-contrast from 12/20/2016 10:00 AM, MR Head 3D unenhanced + contrast from 12/19/20"
      },
      "choice_counts": {
        "B: MR Spine plain + post-contrast from 12/20/2016 10:00 AM, MR Head 3D unenhanced + contrast from 12/19/20": 4,
        "B: MR Head 3D unenhanced + contrast from 12/19/2016 10:30 AM. MR Spine plain + post-contrast from 12/20/20": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "B: MR Spine plain + post-contrast from 12/20/2016 10:00 AM, MR Head 3D unenhanced + contrast from 12/19/20"
    },
    "patient_01_q8": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "A: The patient's medications at discharge include Aspirin 100mg, Atorvastatin 40mg, Sertraline 50mg, Lorazepam 1mg, Melatonin 2mg,",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "A: The patient's medications at discharge include Aspirin 100mg, Atorvastatin 40mg, Sertraline 50mg, Lorazepam 1mg, Melatonin 2mg,",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "A: The patient's medications at discharge include Aspirin 100mg, Atorvastatin 40mg, Sertraline 50mg, Lorazepam 1mg, Melatonin 2mg,",
        "tiiuae/falcon-7b-instruct_NQ": "B: The patient started taking Pregabalin 75 mg, 1-0-1-0\nAnswer:  B: The patient started taking Pregabalin 75 mg, 1-0-1-0",
        "tiiuae/falcon-7b-instruct_Q": "A: The patient's medications at discharge include Aspirin 100mg, Atorvastatin 40mg, Sertraline 50mg, Lorazepam 1mg, Melatonin 2mg,"
      },
      "choice_counts": {
        "A: The patient's medications at discharge include Aspirin 100mg, Atorvastatin 40mg, Sertraline 50mg, Lorazepam 1mg, Melatonin 2mg,": 4,
        "B: The patient started taking Pregabalin 75 mg, 1-0-1-0\nAnswer:  B: The patient started taking Pregabalin 75 mg, 1-0-1-0": 1
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "A: The patient's medications at discharge include Aspirin 100mg, Atorvastatin 40mg, Sertraline 50mg, Lorazepam 1mg, Melatonin 2mg,"
    },
    "patient_01_q9": {
      "choices_by_verifier": {
        "Qwen/Qwen1.5-1.8B-Chat_NQ": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. Based on the context provided, the patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone",
        "mistralai/Mistral-7B-Instruct-v0.3_NQ": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. At admission",
        "mistralai/Mistral-7B-Instruct-v0.3_Q": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. At admission",
        "tiiuae/falcon-7b-instruct_NQ": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. At admission",
        "tiiuae/falcon-7b-instruct_Q": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. At admission"
      },
      "choice_counts": {
        "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. Based on the context provided, the patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone": 1,
        "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. At admission": 4
      },
      "num_valid_choices": 5,
      "agreement_level": "Majority",
      "agreed_upon_choice": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. At admission"
    }
  }
}